An academic experiment has lead to a new class of drug for attacking heart disease.

Researchers found that oxidants are involved in activating the genes that initiate the inflammatory process that causes atherosclerosis and that a modified form of an antioxidant, Probucol (an anticholesterol medication) blocks this process.